Cyclacel Pharmaceuticals Inc expected to post a loss of $5.89 a share - Earnings Preview

Bio Green Med Solution

01/03/2024 11:06

* Cyclacel Pharmaceuticals Inc  CYCC.OQ   CYCC.O  is
expected
to show no change in quarterly revenue when it reports 
results on March 4 (estimated) for the period ending December
31 2023
    * 
    * ​LSEG's mean analyst estimate for Cyclacel Pharmaceuticals
Inc
is for a loss of $5.89 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cyclacel
Pharmaceuticals Inc is $93.00​, above​ its last closing price
of $2.56. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -5.46       -5.45      -7.35     Missed  -34.9
 Jun. 30 2023  -7.61       -7.55      -6.60     Beat    12.6
 Mar. 31 2023  -9.89       -9.95      -7.05     Beat    29.1​
 Dec. 31 2022  -6.77       -7.24      -9.00     Missed  -24.4
 ​​Sep.        -8.21       -8.45      -6.30     Beat    25.4
 30 2022                                                
 Jun. 30 2022  -9.22       -9.38      -6.90     Beat    26.4​
 Mar. 31 2022  -10.30      -10.26     -6.30     Beat    38.6
 Dec. 31 2021              -9.80      -8.10     Beat    17.3
 This summary was machine generated March 1 at 11:06 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)